CL2021002331A1 - Formulaciones de anticuerpo anti-il-36r - Google Patents
Formulaciones de anticuerpo anti-il-36rInfo
- Publication number
- CL2021002331A1 CL2021002331A1 CL2021002331A CL2021002331A CL2021002331A1 CL 2021002331 A1 CL2021002331 A1 CL 2021002331A1 CL 2021002331 A CL2021002331 A CL 2021002331A CL 2021002331 A CL2021002331 A CL 2021002331A CL 2021002331 A1 CL2021002331 A1 CL 2021002331A1
- Authority
- CL
- Chile
- Prior art keywords
- antibody formulations
- formulations
- antibody
- administration
- subject
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940099539 IL-36 receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815405P | 2019-03-08 | 2019-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2021002331A1 true CL2021002331A1 (es) | 2022-06-17 |
Family
ID=70009446
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2021002331A CL2021002331A1 (es) | 2019-03-08 | 2021-09-07 | Formulaciones de anticuerpo anti-il-36r |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11730812B2 (enExample) |
| EP (1) | EP3934617A1 (enExample) |
| JP (2) | JP7420827B2 (enExample) |
| KR (1) | KR20210137520A (enExample) |
| CN (1) | CN113543772A (enExample) |
| AU (1) | AU2020238676B2 (enExample) |
| BR (1) | BR112021016198A2 (enExample) |
| CA (1) | CA3132917A1 (enExample) |
| CL (1) | CL2021002331A1 (enExample) |
| EA (1) | EA202192405A1 (enExample) |
| IL (1) | IL286100B2 (enExample) |
| MX (1) | MX2021010783A (enExample) |
| PH (1) | PH12021552150A1 (enExample) |
| TW (1) | TW202100141A (enExample) |
| WO (1) | WO2020185479A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2914243T3 (es) | 2015-04-15 | 2022-06-08 | Anaptysbio Inc | Anticuerpos dirigidos contra el receptor de la interleuquina 36 (IL-36R) |
| CA3090421A1 (en) * | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| CA3132917A1 (en) | 2019-03-08 | 2020-09-17 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibody formulations |
| KR20230038774A (ko) * | 2020-07-17 | 2023-03-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 호중성 피부병의 치료를 위한 항-il-36r 항체 |
| CN112094349B (zh) * | 2020-11-04 | 2021-02-09 | 上海华奥泰生物药业股份有限公司 | 靶向于白介素36r的抗体及其制备方法和应用 |
| WO2022166977A1 (zh) * | 2021-02-08 | 2022-08-11 | 上海普铭生物科技有限公司 | 抗人il-36r抗体及其应用 |
| EP4301409A1 (en) | 2021-03-04 | 2024-01-10 | Boehringer Ingelheim International GmbH | Methods for the treatment of gpp |
| CA3218343A1 (en) * | 2021-05-12 | 2022-11-17 | Anaptysbio, Inc. | Antibody composition |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| EP0656789B1 (en) | 1992-08-21 | 1997-12-17 | Genentech, Inc. | Method for treating a lfa-1-mediated disorder |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| DK0999853T3 (da) | 1997-06-13 | 2003-04-22 | Genentech Inc | Stabiliseret antostofformulering |
| PT1003861E (pt) | 1997-08-01 | 2007-01-31 | Schering Corp | Proteínas de membrana de células de mamíferos;reagentes relacionados |
| US6416973B1 (en) | 1997-08-01 | 2002-07-09 | Schering Corporation | Nucleic acids encoding mammalian cell membrane protein MDL-1 |
| DK1272647T3 (en) | 2000-04-11 | 2014-12-15 | Genentech Inc | Multivalent antibodies and uses thereof |
| US20040110930A1 (en) | 2002-10-03 | 2004-06-10 | Reinl Stephen J. | Multimeric protein engineering |
| DK1610820T4 (da) | 2003-04-04 | 2013-11-04 | Genentech Inc | Høj-koncentration antistof- og proteinformuleringer |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| ES2438444T3 (es) | 2006-09-08 | 2014-01-16 | Amgen, Inc | Variantes de la familia de IL-1 |
| CA2685015A1 (en) | 2007-04-23 | 2008-11-06 | Schering Corporation | Anti-mdl-1 antibodies |
| CA2691618A1 (en) | 2007-06-29 | 2009-01-08 | Schering Corporation | Mdl-1 uses |
| RU2011105466A (ru) | 2008-08-28 | 2012-10-10 | ВАЙЕТ ЭлЭлСи (US) | Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях |
| WO2011017070A1 (en) | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| PT2473528E (pt) * | 2009-09-03 | 2015-03-04 | Ablynx NV | Formulações estáveis de polipéptidos e seus usos |
| RU2626512C2 (ru) | 2010-03-01 | 2017-07-28 | Цитодин, Инк. | Концентрированные белковые фармацевтические составы и их применение |
| KR102159109B1 (ko) | 2011-11-16 | 2020-09-23 | 베링거 인겔하임 인터내셔날 게엠베하 | 항 ｉｌ-36ｒ 항체 |
| MY164611A (en) * | 2012-01-23 | 2018-01-30 | Regeneron Pharma | Stabilized formulations containing anti-ang2 antibodies |
| EP3943084A1 (en) | 2012-08-24 | 2022-01-26 | Novartis AG | Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling |
| US20180008707A1 (en) | 2015-02-13 | 2018-01-11 | Sanofi | Stable liquid formulation for monoclonal antibodies |
| ES2914243T3 (es) | 2015-04-15 | 2022-06-08 | Anaptysbio Inc | Anticuerpos dirigidos contra el receptor de la interleuquina 36 (IL-36R) |
| DE112015006762T5 (de) | 2015-08-05 | 2018-04-19 | Ford Global Technologies, Llc | Kundenfahrmodus für Fahrzeuge |
| WO2018183173A1 (en) | 2017-03-27 | 2018-10-04 | Boehringer Ingelheim International Gmbh | Anti il-36r antibodies combination therapy |
| CA3090421A1 (en) | 2018-03-14 | 2019-09-19 | Boehringer Ingelheim International Gmbh | Use of anti-il-36r antibodies for treatment of inflammatory bowel disease |
| EP3765513A1 (en) * | 2018-03-14 | 2021-01-20 | Boehringer Ingelheim International GmbH | Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis |
| CN113301955A (zh) | 2018-12-27 | 2021-08-24 | 勃林格殷格翰国际有限公司 | 治疗掌跖脓疱症的抗il-36r抗体 |
| CA3132917A1 (en) | 2019-03-08 | 2020-09-17 | Boehringer Ingelheim International Gmbh | Anti-il-36r antibody formulations |
-
2020
- 2020-03-05 CA CA3132917A patent/CA3132917A1/en active Pending
- 2020-03-05 CN CN202080019100.2A patent/CN113543772A/zh active Pending
- 2020-03-05 MX MX2021010783A patent/MX2021010783A/es unknown
- 2020-03-05 IL IL286100A patent/IL286100B2/en unknown
- 2020-03-05 US US16/809,606 patent/US11730812B2/en active Active
- 2020-03-05 JP JP2021552832A patent/JP7420827B2/ja active Active
- 2020-03-05 AU AU2020238676A patent/AU2020238676B2/en active Active
- 2020-03-05 WO PCT/US2020/021059 patent/WO2020185479A1/en not_active Ceased
- 2020-03-05 PH PH1/2021/552150A patent/PH12021552150A1/en unknown
- 2020-03-05 EA EA202192405A patent/EA202192405A1/ru unknown
- 2020-03-05 KR KR1020217032399A patent/KR20210137520A/ko active Pending
- 2020-03-05 EP EP20714813.1A patent/EP3934617A1/en active Pending
- 2020-03-05 TW TW109107268A patent/TW202100141A/zh unknown
- 2020-03-05 BR BR112021016198A patent/BR112021016198A2/pt unknown
-
2021
- 2021-09-07 CL CL2021002331A patent/CL2021002331A1/es unknown
-
2023
- 2023-07-17 US US18/353,133 patent/US20230372480A1/en active Pending
- 2023-11-13 JP JP2023193220A patent/JP2024020372A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL286100B1 (en) | 2024-08-01 |
| JP2024020372A (ja) | 2024-02-14 |
| MX2021010783A (es) | 2021-09-30 |
| EA202192405A1 (ru) | 2022-01-13 |
| IL286100A (en) | 2021-10-31 |
| US20200282053A1 (en) | 2020-09-10 |
| IL286100B2 (en) | 2024-12-01 |
| WO2020185479A1 (en) | 2020-09-17 |
| CA3132917A1 (en) | 2020-09-17 |
| KR20210137520A (ko) | 2021-11-17 |
| PH12021552150A1 (en) | 2022-08-15 |
| JP2022524502A (ja) | 2022-05-06 |
| TW202100141A (zh) | 2021-01-01 |
| US11730812B2 (en) | 2023-08-22 |
| EP3934617A1 (en) | 2022-01-12 |
| AU2020238676B2 (en) | 2025-04-17 |
| BR112021016198A2 (pt) | 2021-11-03 |
| CN113543772A (zh) | 2021-10-22 |
| AU2020238676A1 (en) | 2021-09-16 |
| JP7420827B2 (ja) | 2024-01-23 |
| US20230372480A1 (en) | 2023-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002331A1 (es) | Formulaciones de anticuerpo anti-il-36r | |
| CL2021000630A1 (es) | Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585) | |
| EP3903817A4 (en) | NOVEL ANTI-CRR8 ANTIBODY | |
| CY1124521T1 (el) | Σκευασματα αντισωματος anti-cd19 | |
| CL2019001554S1 (es) | Automóvil. | |
| EP3981435A4 (en) | FAT COMPOSITION | |
| DK4328309T3 (da) | Lipidsammensætning | |
| BR112019001233A2 (pt) | formulação farmacêutica e uso da mesma | |
| SA521421845B1 (ar) | منتجات مضادة للفيروسات وصيغ نانوية منها | |
| BR112018075644A2 (pt) | anticorpos anti-cd98 e conjugados de anticorpo e fármaco | |
| CL2019002232S1 (es) | Automóvil. | |
| CL2020001201S1 (es) | Automóvil. | |
| CL2020000174S1 (es) | Automóvil. | |
| CO2019013718A2 (es) | Anticuerpos anti-trkb | |
| MA52152A (fr) | Anticorps | |
| IL291131A (en) | Formulations of anti-il-23p19 antibodies | |
| CY1122578T1 (el) | Φαρμακευτικο σκευασμα το οποιο περιλαμβανει αντισωμα | |
| PL3956328T3 (pl) | Stałe postaci modulatora receptora toll-podobnego | |
| IL283886A (en) | Antibody formulations | |
| SG11202102875YA (en) | Anti-fgfr2 antibody formulations | |
| CL2020000376A1 (es) | Compuesto pentacíclico. | |
| EP3885362A4 (en) | Antibody conjugate | |
| EP3827113A4 (en) | SPRAY MOLDING OF STRUCTURAL COMPOUNDS | |
| MX2019014861A (es) | Compuestos de quinolinilciclohexilpropanamida sustituidos y metodos mejorados para su preparacion. | |
| CL2021001300A1 (es) | Gen suicida |